Physician profile
Geoffrey S Lipscomb
NPI 1659317345
$10,768.34
in general payments reported to CMS, 2019-2025
46 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,748 · 2020: $1,539 · 2021: $2,135 · 2022: $1,696 · 2023: $1,021 · 2024: $1,375 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,421 · Consulting Fee: $150 · Education: $78.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,421.20 |
| Consulting Fee | $150.00 |
| Education | $78.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,315.23 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $1,092.20 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $1,014.74 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $977.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $962.59 | 2019-2022 | |
| Novo Nordisk INC | $711.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Paratek Pharmaceuticals, INC. | $497.31 | 2021-2025 | Nuzyra, Xhance |
| Pfizer INC. | $405.41 | 2019-2023 | |
| Allergan, INC. | $395.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $297.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $272.98 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.90 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.34 | 2019-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $227.02 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $199.19 | 2024-2025 | Voquezna |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Lipscomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.